Why the study?
The study was conducted to examine the impact of three types of bariatric surgery compared with dietary intervention on concurrent changes in HOMA-IR and appetite hormones over 3 years.
Does bariatric surgery improve insulin resistance and appetite hormones compared to dietary intervention in adults?
Does bariatric surgery improve insulin resistance and appetite hormones compared to dietary intervention in adults?
Bariatric surgery, particularly Roux-en-Y gastric bypass, significantly reduces insulin resistance compared to dietary intervention, with improvements during weight stability potentially mediated by enhanced PYY and adiponectin secretion.
Answers are grounded in this paper and cite their sources.
RYGB may reduce insulin resistance more than diet in observational data; leaves open randomized confirmation of clinical outcomes.
To examine an impact of three types of bariatric surgery compared with dietary intervention (DIET), on concurrent changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and appetite hormones over 3 years. Fifty-five adults were studied during phase of weight loss (0-12 months) and during weight stability (12-36 months) post intervention. Measurements of HOMA-IR, fasting and postprandial PYY and GLP1, adiponectin, CRP, RBP4, FGF21 hormones and dual-Xray absorptiometry were performed throughout the study. All surgical groups achieved significant reductions in HOMA-IR with greatest difference between Roux-en-Y gastric bypass and DIET (- 3.7; 95% CI - 5.4, - 2.1; p = 0.001) at 12-36 months. Initial (0-12 months) HOMA-IR values were no different to DIET after adjustment for the lost weight. During 12-36 months, after controlling for treatment procedure and weight, for every twofold increase in postprandial PYY and adiponectin, HOMA-IR decreased by 0.91 (95% CI - 1.71, - 0.11; p = 0.030) and by 0.59 (95% CI - 1.10, - 0.10; p = 0.023) respectively. Initial, non-sustained changes in RBP4 and FGF21 were not associated with HOMA-IR values. While initial rapid weight loss reduces insulin resistance, the enhanced secretions of PYY and adiponectin may contribute to weight-independent improvements in HOMA-IR during weight stability.Clinical trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12613000188730.
No takes yet. Share an insight, caveat, or question.
Brzozowska et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: